Sagar Lonial, MD, on Multiple Myeloma: How I Treat Newly Diagnosed Patients

2015 ASH Annual Meeting

Sagar Lonial, MD, of Emory University School of Medicine, summarizes his educational session on this vital topic.

Simon Rule, MD, on MCL: Ibrutinib vs Temsirolimus

Simon Rule, MD, of Derriford Hospital, discusses results from an international, multicenter study in patients with previously treated mantle cell lymphoma (Abstract 469).

David A. Williams, MD

David A. Williams, MD, on the Goals and Highlights of ASH 2015

Outgoing ASH President, David A. Williams, MD, of the Dana-Farber/Boston Children’s Hospital, gives an overview of this year’s Annual Meeting of the American Society of Hematology.

Symptom Management

Alok A. Khorana, MD

Alok A. Khorana, MD, on Preventing Venous Thromboembolism

Alok A. Khorana, MD, of the Cleveland Clinic, discusses study results on the use of dalteparin for thromboprophylaxis in cancer patients at high risk for the condition (Abstract 427).

Lymphoma

Stephen J. Schuster, MD

Stephen J. Schuster, MD, on CD19+ Lymphomas: Sustained Remissions in Relapsed or Refractory Disease

Stephen J. Schuster, MD, of the University of Pennsylvania, discusses the findings of a study of chimeric antigen receptor modified T cells directed against CD19 in patients with relapsed or refractory disease (Abstract 183).

Lymphoma

Julie Vose, MD, MBA, and Cameron J. Turtle, MBBS, PhD

Julie Vose, MD, MBA, and Cameron J. Turtle, MBBS, PhD, on B-Cell NHL and CLL: Clinical Trial Results on T-Cell Therapy

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and Cameron J. Turtle, MBBS, PhD, of the Fred Hutchinson Cancer Research Center, discuss anti-CD19 chimeric antigen receptor-modified T-cell therapy and clinical outcome (Abstract 184).

Apr

Today In Oncology

Sagar Lonial, MD, on Multiple Myeloma: How I Treat Newly Diagnosed Patients

Related Videos

Simon Rule, MD, on MCL: Ibrutinib vs Temsirolimus

David A. Williams, MD, on the Goals and Highlights of ASH 2015

Alok A. Khorana, MD, on Preventing Venous Thromboembolism

Stephen J. Schuster, MD, on CD19+ Lymphomas: Sustained Remissions in Relapsed or Refractory Disease

Julie Vose, MD, MBA, and Cameron J. Turtle, MBBS, PhD, on B-Cell NHL and CLL: Clinical Trial Results on T-Cell Therapy

Sequential or Concurrent Radiotherapy and Immunotherapy in Advanced Newly Diagnosed or Refractory NSCLC

Romiplostim for Chemotherapy-Induced Thrombocytopenia

AYA Cancer Survivors and Risk for Earlier Subsequent Primary Neoplasms

Bispecific Antibody Shows Deep Remission in Patients With Relapsed/Refractory Follicular Lymphoma

Is Standard of Care Optimal for the Individual Patient?